Milestone's options
What cardio play Milestone plans to do with its upsized $55M series C round.
Milestone Pharmaceuticals Inc. turned positive Phase II data for etripamil into an upsized $55 million series C round, which will give the cardiovascular company leeway to expand its core program or in-license a second
